Utilizing Precision Medicine to elucidate the mechanisms underpinning treatment efficacy

项目总结： 精确肿瘤学仍处于初级阶段，虽然团体设想基于以下方面的反应进行个性化护理 在单个肿瘤中，精确医疗管道产生的数据具有广泛的潜在用途。 检查与英格兰精密研究所合作进行的迭代药物筛选的数据 本项目旨在研究支持两种PI3K抑制剂疗效的分子机制 基于组合的。具体目的一是探索野生型和野生型PLK磷酸化的影响 突变的PI3K，以了解这种相互作用的后果，并确定哪些患者可能 受益于PLK和PI3K抑制剂的联合治疗。第二个目标是试图理解 PI3K抑制剂治疗对胰岛素释放的影响，并询问治疗反应是否可以 通过阻止这种反馈来改进。通过这种方式，这个项目将试图解释分子 从我们的精准医疗渠道观察并寻求识别患者身份的机制 将从这些治疗方法中受益的人群。

Project Summary: Precision oncology is still in its infancy, and while groups envision personalizing care based on the responses of individual tumors there are a wide array of potential uses for the data generated by precision medicine pipelines. Examining data from iterative drug screening performed in collaboration with the Englander Institute of Precision Medicine this project seeks to examine the molecular mechanisms that underpin the efficacy of two PI3K inhibitor based combinations. Specifically aim one explore the impact of the PLK phosphorylation of both wildtype and mutant PI3K to understand the ramifications of this interaction and to identify patient populations who could benefit from combination treatment with PLK and PI3K inhibitors. The second aim seeks to understand the impact of the insulin release that occurs with PI3K inhibitor treatments, and to ask if therapeutic responses can be improved by preventing this feedback. In this manner this project will seek to explain the molecular mechanisms that underlie observations from our precision medicine pipeline and seek to identify patient populations that would benefit from these therapeutic approaches.